Current Report Filing (8-k)
November 10 2016 - 10:42AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
November 10, 2016
ABEONA THERAPEUTICS INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
0-9314
|
83-0221517
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
3333 Lee Parkway, Suite 600
Dallas, TX 75219
(Address of principal executive offices)
(Zip Code)
(214)-665-9495
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General
Instruction A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02. Results of Operations and Financial
Condition.
On November 10, 2016, Abeona Therapeutics
Inc. issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2016.
The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.
The information in Item 2.02 of this
Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01.
Financial Statements
and Exhibits.
(d) Exhibits.
Exhibit No.
|
Description
|
|
|
|
99.1
|
|
Press release dated November 10, 2016, entitled “Abeona Therapeutics Inc. Announces Third Quarter 2016 Financial Results and Recent Clinical Highlights”
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Abeona Therapeutics Inc.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
By:
|
/s/ Stephen B. Thompson
|
|
|
|
Stephen B. Thompson
Vice President Finance
Chief Accounting Officer
|
|
Dated: November 10, 2016
EXHIBIT INDEX
Exhibit Number
|
|
|
|
99.1
|
|
Press release dated November 10, 2016, entitled “Abeona Therapeutics Inc. Announces Third Quarter 2016 Financial Results and Recent Clinical Highlights”
|
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024